In the age of COVID-19, many cannabis events have migrated to online forums, serving investors at home hoping to listen in on the latest expert insights.

This past Monday and Tuesday (June 22 to 23), the Prohibitions Partners LIVE event offered the latest tidbits on the marijuna industry at large. Overall, it showed cannabis market experts are hopeful about the future of the space as investors become more mature.


Among the guests was Alan Brochstein, marijuana analyst and industry commentator with 420 Investor and New Cannabis Ventures. While recapping the path that has led to the current state of the market, he emphasized an overall theme for modern cannabis investment: There is no more easy money.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Brochstein said he’s been seeing companies, particularly multi-state operators (MSOs) in the US, opt for sale-leaseback deals or debt offerings as a way to keep afloat rather than raising capital. While these tactics offer alternatives for companies, the analyst expressed some concern about the impact of cash flow when it comes to the terms of debt agreements.

As a warning sign for investors, Brochstein pointed to the partial conversion of convertible debt deals done by Canadian cannabis giants Aphria (NASDAQ:APHA,TSX:APHA) and HEXO (NYSE:HEXO,TSX:HEXO).

“It’s an existential problem for those that don’t have great access to capital,” he said.

Changing cannabis investment tactics and landscape

Connected to the lack of easy money is the evolution of the cannabis play for investors. A number of conversations at the event concentrated on the sector’s progression from hype-based interest to what many advocates hope is a more settled, mature market based on fundamentals.

During a conversation surrounding the North American markets, Trulieve (CSE:TRUL,OTCQX:TCNNF) CEO Kim Rivers said she still remembers times when potential investors would drill into why Trulieve wouldn’t move ahead with expansions into other states.

Trulieve has distinguished itself from its fellow MSOs by focusing on its active assets in Florida, despite increasing competition in the state’s legalized medical cannabis market.

According to numbers from the Florida Department of Health’s Office of Medical Marijuana Use, Trulieve has over 10 more stores than its closest publicly traded competitor, which is Curaleaf Holdings (CSE:CURA,OTCQX:CURLF). Throughout 2020, Trulieve has come out on top in the weekly sales reports from the state agency.

Rivers praised the analysts who have made the effort to establish why bigger isn’t always better in the cannabis industry.

In his talk, Brochstein echoed the sentiment of rewarding a more simple and direct cannabis business approach. In fact, he went as far as to say that investors will penalize complexity.

Due to the emerging nature of the industry, Brochstein said companies pride themselves on offering very convoluted and expanding business models, and that has led to some investors getting burned.

Now the majority of retail investors, who are still the largest demographic in the cannabis space, according to Brochstein, are pursuing simpler models, with cash flow being a key indicator of success.

What happened with US marijuana legalization?

The Prohibition Partners LIVE event also served as a public reckoning for the much-anticipated legalization of cannabis in the US. Many hoped it would happen swiftly following Canada’s legalization of recreational cannabis in October 2018, and at the time insiders in the space began evaluating the chances for the US to move ahead as well.

Instead it’s been a slow and complicated process.

The US cannabis market has continued to be affected by the fractured nature of the country’s legalization process. During the Prohibition Partners LIVE event, several experts discussed what could be coming for the American market by way of critical changes needed.

When asked about the potential for more investors to jump aboard the cannabis train, Rivers was quick to point out pieces of reform that could help the market, such as the SAFE Banking Act, which she believes would definitely invite a broader set of investors to come in.

“Look, is the investor pool as deep as we would like? The answer to that is no,” said Rivers. “I think the real catalyst there will come, of course, when we’re able to uplist into a US exchange.”

The key, as has always been with cannabis investments, is compliance.

Brochstein mentioned that he could see small reforms as a way to offer protections for US-based financial institutions seeking to do business with cannabis firms, act as a catalyst for the sector. But most likely a political change will be needed to make these changes a reality.

“Unfortunately, it probably takes the Democrats controlling the Senate, which they don’t have now, and the House. If that happens, no matter who the president is, I think we might see some regulatory reforms,” Brochstein said.

But what would these reforms offer? For starters, they could make it so companies like Trulieve and other MSOs could list in the US markets; additionally, this event could open the door to more institutions to step in and explore more meaningful investments.

Brochstein suggested banks should have protections to take deposits or make loans to cannabis corporations. It would also help if credit card processors could receive protections, the analyst said.

“All that’s going on in the US financial market right now is out of caution and a lack of clarity, it’s not illegal,” Brochstein said. “If we could get the large MSOs onto the NASDAQ and the New York Stock Exchange … that would be a game changer.”

In his own talk, Narbe Alexandrian, CEO of cannabis investment firm Canopy Rivers (TSX:RIV,OTC Pink:CNPOF), said modern cannabis companies and their investors need to adjust to a long-term view of the industry. Alexandrian expects legalization to arrive in the US in the next two to five years.

Similar to the other experts, Alexandrian said full legalization of cannabis in the US would bring larger institutional investors into the space, drive up valuations and increase competition.

Investor takeaway

Cannabis investments have offered a rocky road for those willing to take a go in the industry, but experts are becoming more upbeat about the metrics being used to evaluate participants.

Now industry observers have to wait and see when the desired catalysts will arrive for the marijuana stock market.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 
  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less